Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or Refractory AML
研究概览
简要总结
This clinical trial uses a laboratory test called a high throughput sensitivity assay in planning treatment for patients with relapsed or refractory acute myeloid leukemia. The aim is to try to identify drugs that may be effective in killing leukemia cells for those patients who will not be cured with conventional chemotherapy. This assay will test multiple drugs simultaneously against a patient's own donated blood sample. The goal is to use this laboratory assay to best match a drug to a patient's disease.
详细描述
PRIMARY OBJECTIVES:
I. To obtain results from a high throughput drug sensitivity assay within 10 days, procure drug within 14 days and initiate treatment within 21 days.
SECONDARY OBJECTIVES:
I. To achieve a response (cytoreduction or at least partial response) greater that than expected for comparable refractory patient populations with other salvage regimens.
OUTLINE:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of acute myeloid leukemia by World Health Organization (WHO) criteria (except acute promyelocytic leukemia), acute leukemias of ambiguous lineage by WHO criteria, or myelodysplastic syndrome refractory anemia with excess blasts (RAEB)-2 by WHO classification or advanced myeloproliferative neoplasm with >= 10% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML)-2 by WHO classification who have failed 2 inductions at initial diagnosis or failed >= 2 salvage regimens for relapsed acute myeloid leukemia (AML)
- •Patients who have had a 1st remission for >= 1 year must have received cytotoxic chemotherapy as a salvage regimen
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 - 3
- •Expectation that we can obtain about 100 million blasts from blood and/or marrow (for example, circulating blast count of 5,000 or greater)
- •Bilirubin =< 1.5 x institutional upper limit of normal (IULN) unless elevation is thought to be due to Gilbert's syndrome, hemolysis, or hepatic infiltration by the hematologic malignancy
- •Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum pyruvate glutamate transaminase (SPGT) (alanine aminotransferase [ALT]) =< 2.5 x IULN, unless elevation in thought to be due to hepatic infiltration by the hematologic malignancy
- •Alkaline phosphatase =< 2.5 X ULN
- •Serum creatinine =< 2.0 mg/dL
- •Stable or improving on appropriate antimicrobial therapy for infection, without ongoing fever
- •Informed consent
- •Willing to use contraception
排除标准
- •No other concomitant treatment for leukemia
- •No other active cancer that requires systemic chemotherapy or radiation
- •Significant organ compromise that will increase risk of toxicity or mortality
- •Pregnancy or lactation
研究组 & 干预措施
Treatment (chemotherapy, biological therapy)
Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
干预措施: chemotherapy (Drug)
Treatment (chemotherapy, biological therapy)
Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
干预措施: antitumor drug screening assay (Other)
Treatment (chemotherapy, biological therapy)
Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
干预措施: biological therapy (Biological)
结局指标
主要结局
Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or Refractory AML
时间窗: Up to 21 days
Whether treatment was administered in the time frame based on the high throughput drug screen. Time from sample procurement to assay results.
次要结局
- Rate of Complete Response, Defined by Criteria of Cheson et al.(Baseline up to 2 years)
研究者
Pamela S Becker
Principal Investigator
University of Washington